Bills/S. 1702

Access to Prescription Digital Therapeutics Act of 2025

Access to Prescription Digital Therapeutics Act of 2025

In CommitteeHealthcareSenateSenate Bill · 119th Congress
Bill Progress · Senate
Introduced
Committee
Passed House
Passed Senate
Passed Both
Signed

Plain Language Summary

# Access to Prescription Digital Therapeutics Act of 2025 - Summary **What the Bill Would Do** This bill would allow Medicare and Medicaid to cover and pay for prescription digital therapeutics—software applications designed to help prevent, manage, or treat medical conditions. Currently, these digital health tools may not be consistently covered by these government insurance programs. The bill requires the Centers for Medicare & Medicaid Services (CMS) to create a payment system for manufacturers, taking into account factors like how long patients use the software. Manufacturers would also have to report information about coverage from private insurance companies, with financial penalties for non-compliance. **Who It Affects** This bill primarily affects Medicare and Medicaid beneficiaries who could gain access to digital therapy tools, manufacturers of these applications, and potentially private insurance companies.

Patients with chronic conditions or mental health issues could benefit if their digital treatments become covered by government insurance. Manufacturers would need to navigate new reporting requirements and payment structures. **Current Status** The bill was introduced in the Senate and is currently in committee, meaning it has not yet been voted on by either chamber of Congress. It would need to pass both the Senate and House before being sent to the President for approval.

CRS Official Summary

Access to Prescription Digital Therapeutics Act of 2025This bill provides for Medicare and Medicaid coverage of prescription digital therapeutics (i.e., software applications that are used to prevent, manage, or treat medical conditions). The Centers for Medicare & Medicaid Services must establish a Medicare payment methodology for payments to manufacturers that takes into account certain factors (e.g., ongoing use); manufacturers must report specified information about private payors, subject to civil penalties.

Advertisement

Latest Action

May 8, 2025

Read twice and referred to the Committee on Finance.

Sponsor

3 cosponsors

Key Dates

Introduced
May 8, 2025
Last Updated
May 8, 2025
Read Full Text on Congress.gov →
Advertisement